"In this six-month extension to the trial, we found that most adults continued to use CGM almost every day, and had sustained benefits in diabetes control as measured by HbA1c levels and the amount of time blood sugar was in the target range," said Dr. Aaron Kowalski, Program Director for Metabolic Control at JDRF. "These benefits persisted despite less intensive follow-up over the second half of the trial than the first, which was designed to approximate usual clinical practice."
He noted that just as important as the persistence of control that CGM devices helped patients achieve was the remarkably low rate of severe hypoglycemic events during the second six months of the study. Severe hypoglycemic events which required the assistance of another person or medical professional were experienced by 10% of the study participants during the first six months of the trial, but only by 4% in the second six months. The rate of severe hypoglycemic events fell from 21.8 events per 100 person-years during the first six months to 7.1 events per 100 person-years during the second six months. The rate was not associated with the HbA1c level of the trial participants at the time the study began.
According to Dr. Tamborlane, an investigator in both the JDRF CGM Trial and DCCT trials, the rate of severe hypoglycemia in people using CGM devices during the second six months of the JDRF trial was markedly lower than in the Diabetes Control and Complications Trial intensive treatment group seven hypoglycemia events compared with 62 in the DCCT trial even though the mean HbA1c of JDRF trial participants at 6.8% was lower than the DCCT trial participants' level of 7.1%.
"Plus, the total absence of severe hypoglycemia during the s
|Contact: Joana Casas|
Juvenile Diabetes Research Foundation International